1,893 reports of this reaction
3.6% of all SORAFENIB reports
#3 most reported adverse reaction
HEPATOCELLULAR CARCINOMA is the #3 most commonly reported adverse reaction for SORAFENIB, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 1,893 FDA adverse event reports linking SORAFENIB to HEPATOCELLULAR CARCINOMA. This represents approximately 3.6% of all 51,866 adverse event reports for this drug.
Patients taking SORAFENIB who experience hepatocellular carcinoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATOCELLULAR CARCINOMA is moderately reported among SORAFENIB users, representing a notable but not dominant share of adverse events.
In addition to hepatocellular carcinoma, the following adverse reactions have been reported for SORAFENIB:
The following drugs have also been linked to hepatocellular carcinoma in FDA adverse event reports:
HEPATOCELLULAR CARCINOMA has been reported as an adverse event in 1,893 FDA reports for SORAFENIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATOCELLULAR CARCINOMA accounts for approximately 3.6% of all adverse event reports for SORAFENIB, making it one of the most commonly reported side effect.
If you experience hepatocellular carcinoma while taking SORAFENIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.